| |
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Register now and SAVE $300 until February 23 to take your TMF to the next level. Sign up today!
|
|
Today’s Big NewsFeb 14, 2024 |
| By Max Bayer Vertex may be the front-runner in the pursuit of a new non-opioid pain option, but one new biotech is emerging from stealth to mount a challenge with $135 million and a phase 1 clinical candidate. |
|
|
|
By James Waldron Before being swayed by antibody-drug conjugates, one of GSK’s passion projects was oligonucleotides. As part of this romance, the British Big Pharma signed a research collaboration with Elsie Biotechnologies last summer and has now decided to cement the relationship on Valentine’s Day. |
By Gabrielle Masson Earlybird Health is taking flight with 173 million euros ($186 million), a nest egg that will go toward European healthcare companies ranging from early development to late-stage tech nearing regulatory approval and commercialization. |
Sponsored by Questex Fierce Life Sciences and Healthcare sit down with biotech, pharma, and healthcare executives at Fierce JPM Week. |
By Gabrielle Masson Roivant’s Hemavant has discontinued development of its only asset, a former Eisai drug dubbed RVT-2001 that was being studied in a midstage trial for patients with myelodysplastic syndromes. |
By Nick Paul Taylor Replicate Bioscience has early evidence its self-replicating RNA technology works in humans. The Apple Tree Partners biotech showed all doses of its rabies vaccine triggered protective responses, providing an initial sign of the potential of a platform with applications in infectious diseases and cancer. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By James Waldron Grifols is readying an approval run at U.S. and European regulators on the back of a phase 3 win for its concentrated form of a blood clotting factor. |
By Fraiser Kansteiner Even as Australia’s CSL continues to grow, the company’s ambitions for its kidney disease and iron deficiency outfit Vifor Pharma—now known as CSL Vifor—have become more muted. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
|
|---|
|
|
|
Wednesday, February 28, 2024 | 11am ET / 8am PT While oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now!
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
